Shaikh Firdous, Sodhi Sonia Kaur, Kale Lata M, Farooqui Zeenat Fatema, Farooqui Aamena
Senior Lecture, Department of Oral Medicine and Radiology, Rural Dental College, Pravara Medical Trust-Pravara Institute of Medical Sciences, Aurangabad, Maharashtra, India.
Department of Oral Medicine and Radiology, Csmss Dental College and Hospital, Aurangabad, Maharashtra, India.
J Cancer Res Ther. 2023 Jul-Sep;19(5):1206-1211. doi: 10.4103/jcrt.jcrt_1291_21.
The foundation of oncology treatment as a single modality approach as well as the "multimodality" concept has been studied by statistical evaluation pre, during, and posttreatment to rule out their efficacy, expected prognosis, toxicity reactions, and overall survival for the patient. Such studies have also provided an appreciable amount of data for future custom utility. "Targeted therapy" is a cancer treatment that uses drugs but is different from traditional chemotherapy. It works by targeting cancer-specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Researchers are developing drugs that target specific molecular changes. The drugs can block or turn off signals that tell cancer cells to grow and divide, keep cells from living longer than usual, and destroy the cancer cells.
The aim of the study is to carry out a systematic review of clinical trials of molecular targeted therapy in the treatment of cancer.
The objective of the study is to evaluate the efficacy of molecular targeted therapy in the treatment of head-and-neck cancers.
A group of keywords was preselected to search for scientific articles on a web-based database of PubMed. Only completed randomized controlled trials published in the past 5 years in the English language were included with open access. All the selected articles were subjected to the Cochrane bias tool and PRISMA guidelines to extract results.
Among 4 studies specifying the progression-free survival (PFS) for comparing the groups treated either using targeted therapy or other modality/placebo, 50% of studies show a slight increase in PFS in the group treated with TT and other 50% show PFS increase in the non-TT group. Thus, insufficient evidence is furnished to provide a statement and acknowledged the expectancy of a disease-free period with or without the use of TT in the treatment of head-and-neck cancer.
Considering very little information on enhanced effect and presence of evidence supporting an increased risk of adverse events, the addition of TT to treatment is a question to the dilemma. A systematic review intends advantageous in providing foresight for oncologists concerning patient assessment and evaluation to defend inclination proceeding toward the treatment defined.
肿瘤治疗作为单一模式方法以及“多模式”概念的基础，已通过治疗前、治疗期间和治疗后的统计评估进行研究，以排除其对患者的疗效、预期预后、毒性反应和总生存期。此类研究还为未来的定制应用提供了大量数据。“靶向治疗”是一种使用药物的癌症治疗方法，但不同于传统化疗。它通过靶向促成癌症生长和存活的癌症特异性基因、蛋白质或组织环境来发挥作用。研究人员正在开发针对特定分子变化的药物。这些药物可以阻断或关闭促使癌细胞生长和分裂的信号，阻止细胞存活时间超过正常水平，并破坏癌细胞。
本研究的目的是对分子靶向治疗癌症的临床试验进行系统评价。
本研究的目标是评估分子靶向治疗在头颈部癌症治疗中的疗效。
预先选择一组关键词，在基于网络的PubMed数据库中搜索科学文章。仅纳入过去5年以英文发表的、开放获取的完整随机对照试验。所有选定的文章均采用Cochrane偏倚工具和PRISMA指南提取结果。
在4项明确无进展生存期（PFS）以比较接受靶向治疗或其他模式/安慰剂治疗组的研究中，50%的研究显示接受靶向治疗组的PFS略有增加，另外50%的研究显示非靶向治疗组的PFS增加。因此，没有足够的证据来提供一种说法，并确认在头颈部癌症治疗中使用或不使用靶向治疗时无病期的预期。
考虑到关于增强效果的信息非常少，且有证据支持不良事件风险增加，在治疗中添加靶向治疗是一个两难问题。系统评价有助于为肿瘤学家在患者评估和评价方面提供前瞻性见解，以支持倾向于既定治疗方法的选择。
